Tianjin TEDA Biomedical Engineering Co (HKSE:08189) ROCE %: -294.55% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08189 Tianjin TEDA Biomedical Engineering Co Ltd HKSE:08189
28 GF Score
Price HK$0.26
GF Value HK$0.19
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tianjin TEDA Biomedical Engineering Co ROCE %?

Tianjin TEDA Biomedical Engineering Co HKSE:08189 -1.92% 28 ROCE % is -294.55% as of Dec. 2025. GuruFocus rates HKSE:08189 with a GF Score™ of 28/100 and a GF Value™ of HK$0.19 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tianjin TEDA Biomedical Engineering Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -294.55%.

Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tianjin TEDA Biomedical Engineering Co ROCE % Related Terms

Tianjin TEDA Biomedical Engineering Co ROCE % Historical Data

* Premium members only.

The historical data trend for Tianjin TEDA Biomedical Engineering Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin TEDA Biomedical Engineering Co ROCE % Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.64 -12.19 -6.58 -47.36 -337.50

Tianjin TEDA Biomedical Engineering Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.07 -8.17 -85.90 -14.35 -294.55
HKSE:08189
28GF Score
Tianjin TEDA Biomedical Engineering Co Ltd HKSE:08189
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin TEDA Biomedical Engineering Co ROCE % Calculation

Tianjin TEDA Biomedical Engineering Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-120.577/( ( (355.03 - 297.95) + (292.579 - 278.205) )/ 2 )
=-120.577/( (57.08+14.374)/ 2 )
=-120.577/35.727
=-337.50 %

Tianjin TEDA Biomedical Engineering Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-226.89/( ( (453.799 - 314.116) + (292.579 - 278.205) )/ 2 )
=-226.89/( ( 139.683 + 14.374 )/ 2 )
=-226.89/77.0285
=-294.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -294.55% mean?
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a ROCE % of -294.55% as of Dec. 2025.
Is Tianjin TEDA Biomedical Engineering Co's ROCE % too high?
Tianjin TEDA Biomedical Engineering Co's current ROCE % is -294.55%. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's ROCE % compare to CTVA and CF?
Tianjin TEDA Biomedical Engineering Co's ROCE % of -294.55% can be compared against companies in the Agriculture industry. The industry median ROCE % is 8.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for an Agriculture company?
The median ROCE % among Agriculture companies is 8.91, based on 254 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Agriculture industry, the median ROCE % is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current ROCE % is -294.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current ROCE % is -294.55%. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current ROCE % is -294.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued. The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19. GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.

Key valuation signals for HKSE:08189:

  • ROCE %: -294.55%
  • GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
  • GF Score™: 28/100 with 8 warning signs

No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianjin TEDA Biomedical Engineering Co Business Description

Other Exchanges TJJ:Germany
Address No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score

Get the complete analysis for HKSE:08189

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.26
Price
HK$0.19
GF Value